Why the study?
Does zonisamide improve spasm cessation and EEG evolution in patients with symptomatic infantile spasms?
Does zonisamide improve spasm cessation and EEG evolution in patients with symptomatic infantile spasms?
Zonisamide may be an effective and well-tolerated treatment option for achieving spasm cessation and EEG improvement in a subset of patients with symptomatic infantile spasms.
May warrant trial in refractory symptomatic infantile spasms; leaves open efficacy without controlled data.
The authors evaluated zonisamide for symptomatic infantile spasms in 23 patients. Spasm cessation, EEG evolution, and tolerability were assessed for a mean duration of 6.5 months. Six patients (26%) had complete control with cessation of spasms and clearing of hypsarrhythmia. Mean latency time from onset of zonisamide treatment to complete spasm control was 19 days. There were no discontinuations due to adverse effects.
No takes yet. Share an insight, caveat, or question.
Lotze et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: